Abstract: The disclosure relates to a glass product or glass composition, and to a method of making a glass product. The glass composition can be manufactured without inhomogeneities in the glass melt and with sufficiently uniform and isotropic properties in the obtained products. The glass compositions further minimise and/or overcome the problem of blockage of pipes, liners, ducts or nozzles during the manufacture of high-quality glasses.

Abstract: The present invention provides, among other things, compositions and methods for reducing oxidation of a complex comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), for treating diseases and complications of prematurity. In some embodiments, the methods comprise adding antioxidants. In some embodiments, the antioxidants are methionine or sodium thiosulfate. In some aspects, the compositions provided are stable, pure and potent compositions comprising IGF-1 and IGFBP-3. In some aspects, the formulation is lyophilized.

Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(triflu-oromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl] [2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of car-diopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hyperten-sion (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pu

Abstract: Techniques for modifying data within a virtual space are discussed herein. A communication platform may receive a request from a user profile associated with a virtual space. The request may include instruction(s) for the communication platform to perform a modifying operation on data within a virtual space. Based on receiving the request, the communication platform may identify the data on which the operation is to be performed. The communication platform may input the data to one or more machine-learning models trained to output data that is a modified version of the data input to the machine-learning model (e.g., modified data). In such cases, the modified data may be modified consistent with the requested operation. The communication platform may receive the modified data from the machine-learning model and cause the modified data to be displayed via a user interface associated with the user profile.

Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 3-substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)azacycles of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and muscarinic receptor antagonists for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of a muscarinic receptor antagonist and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and P2X3 receptor antagonists for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and norepinephrine reuptake inhibitors for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of a noradrenaline reuptake inhibitor and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 2,3-Dihydrobenzo[b][1,4]dioxin-2-ylmethyl)piperazin-1-yl derivates of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: A glass article is designed at least in part in the form of a glass tube element including at least one shell which encloses at least one lumen. For at least one light transmission analysis of the glass article, a ratio of an average amplitude transmission factor and a specific amplitude transmission factor is greater than 1.00001.

Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmon

Abstract: Techniques for transcribing and/or summarizing multimedia collaboration sessions are discussed herein. For example, users can communicate within a teleconferencing meeting associated with a channel. In some examples, a first machine learning model may be configured to receive audio-visual data and user interaction data (e.g., selected emojis, detected gestures, messages or text input by a user, a thread of messages, etc.) and output a teleconferencing meeting summary. In some examples, the teleconferencing meeting summary can include one or more highlights, action items, and/or artificial intelligence (AI) notes generated using a machine learning model(s).

Abstract: Methods, systems, apparatuses, devices, and computer program products are described. A group-based communication system may support automatic layout updates for a document space. If a user adds an object into the document space, the system may generate a card representing the object. The card may include a link to a resource external to the document space and a preview image for the object, where the preview image may be rendered based on unfurling the link. The system may update a layout of the document space to include the generated card and may send, for display in a user interface (UI) of a user device, the updated layout. In some examples, a user may select to reposition the card within the UI (e.g., by dragging-and-dropping the card within the document space). The system may further update the layout of the document space based on the repositioning of the card.

Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmo

Abstract: Various examples are directed to systems, methods, and apparatuses for providing an interactive developer interface of a group-based communication system. Various examples are directed to systems, methods, and apparatuses for consolidating application data associated with an application within a group-based communication interface. Various examples are directed to systems, methods, and apparatuses for indexing processing actions associated with a plurality of applications.

Abstract: Techniques for providing a suggested message to a user of a communication platform are described herein. The communication platform can receive a request, from a first user, to suggest a message (e.g., suggested message) to a second user with whom the first user is connected via the communication platform. The request can include contents of the suggested message and a user identifier associated with the second user. In some examples, the request can additionally include a suggested virtual space via which the suggested message is to be published, a suggested time for delivery, and/or the like. The communication platform can cause a presentation of the suggested message to the second user, such as via a user interface. In response to receiving an approval of the suggested message via the user interface, the communication platform can cause a publication thereof in association with a user account of the second user.